Apimeds Pharmaceuticals US (APUS) Operating Income (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted Operating Income of -$7.0 million for Q4 2025, down 281.73% on a QoQ basis from -$1.8 million in Q3 2025, and down 2454.32% year-over-year from $299026.3 in Q4 2024.

Apimeds Pharmaceuticals US (APUS) Operating Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's Operating Income history runs 2 years deep, the most recent figure standing at -$7.0 million for Q4 2025.

  • Quarterly Operating Income fell 2454.32% year-over-year to -$7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.9 million (down 834.25% YoY) and the FY2025 annual result came in at -$11.9 million, down 834.25% from the prior year.
  • Operating Income was -$7.0 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$1.8 million in the prior quarter.
  • Across five years, Operating Income topped out at -$271726.0 in Q1 2024 and bottomed at -$7.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 652.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 833.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -2.65 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 325.80 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -79.70 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 193.40 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 291.00 Mn
10 Apimeds Pharmaceuticals US 8.17 Mn 8.17 Mn - -7.04 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.04 Mn
Sep 30, 2025 -1.84 Mn
Jun 30, 2025 -2.66 Mn
Mar 31, 2025 -364,368.00
Dec 31, 2024 -275,613.00
Sep 30, 2024 -299,999.00
Jun 30, 2024 -427,757.00
Mar 31, 2024 -271,726.00